curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Company profile
Ticker
CRIS
Exchange
Website
CEO
James Dentzer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...
SEC CIK
Corporate docs
Subsidiaries
Curis Securities Corporation • Curis Royalty LLC ...
IRS number
43505116
CRIS stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Curis Provides Third Quarter 2023 Business Update
2 Nov 23
8-K/A
Material Modifications to Rights of Security Holders
28 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
28 Sep 23
DEF 14A
Definitive proxy
18 Aug 23
PRE 14A
Preliminary proxy
4 Aug 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Curis Provides Second Quarter 2023 Business Update
3 Aug 23
424B5
Prospectus supplement for primary offering
6 Jul 23
8-K
Curis Announces $15.1 Million Registered Direct Offering
6 Jul 23
Transcripts
CRIS
Earnings call transcript
2023 Q3
2 Nov 23
CRIS
Earnings call transcript
2023 Q2
3 Aug 23
CRIS
Earnings call transcript
2023 Q1
4 May 23
CRIS
Earnings call transcript
2022 Q4
13 Mar 23
CRIS
Earnings call transcript
2022 Q3
10 Nov 22
CRIS
Earnings call transcript
2022 Q2
5 Aug 22
CRIS
Earnings call transcript
2022 Q1
5 May 22
CRIS
Earnings call transcript
2021 Q4
25 Feb 22
CRIS
Earnings call transcript
2021 Q3
10 Nov 21
CRIS
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm | 25.01 mm |
| Cash burn (monthly) | (no burn) | 456.17 k | 4.12 mm | 3.86 mm | 2.73 mm | 3.38 mm |
| Cash used (since last report) | n/a | 1.06 mm | 9.56 mm | 8.96 mm | 6.32 mm | 7.83 mm |
| Cash remaining | n/a | 23.95 mm | 15.45 mm | 16.05 mm | 18.69 mm | 17.18 mm |
| Runway (months of cash) | n/a | 52.5 | 3.7 | 4.2 | 6.9 | 5.1 |
Institutional ownership, Q3 2023
46.8% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 37 |
| Opened positions | 3 |
| Closed positions | 27 |
| Increased positions | 1 |
| Reduced positions | 30 |
| 13F shares | Current |
|---|---|
| Total value | 12.77 bn |
| Total shares | 2.75 mm |
| Total puts | 0.00 |
| Total calls | 215.70 k |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 626.95 k | $5.14 mm |
| Maverick Capital | 582.27 k | $3.84 bn |
| M28 Capital Management | 421.95 k | $2.78 bn |
| Kingdon Capital Management, L.L.C. | 309.15 k | $2.04 bn |
| Vanguard | 179.87 k | $1.19 bn |
| Artal | 105.00 k | $692.00 k |
| C Citigroup | 91.87 k | $605.43 mm |
| Renaissance Technologies | 85.56 k | $564.00 k |
| Alyeska Investment | 78.14 k | $514.91 mm |
| BLK Blackrock | 53.50 k | $352.53 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 May 23 | Jonathan B. Zung | Employee stock option Common Stock | Grant | Acquire A | No | No | 0.83 | 500,000 | 415.00 k | 500,000 |
| 23 Jan 23 | Anne Elizabeth Borgman | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
| 23 Jan 23 | Marc Rubin | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
| 23 Jan 23 | Martyn D Greenacre | Non Qualified Stock Option Common Stock | Grant | Acquire A | No | No | 0.75 | 85,000 | 63.75 k | 85,000 |
News
Curis Announces Three Presentations At ASH
6 Dec 23
Curis Enters Into Agreement For Emavusertib / Pembrolizumab Combination Study In Melanoma
5 Dec 23
Why Genesco Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Friday's Mid-Day Session
1 Dec 23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
29 Nov 23
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
22 Nov 23